Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.cd008414PMID 15674913
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cited by this paper
• Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis.

  1994cited by this paper
• Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience.

  1994cited by this paper
• Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis.

  1994cited by this paper
• Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.

  1993cited by this paper
• [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].

  1993cited by this paper
• 5-aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study.

  1991cited by this paper

• Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2024 for the Clinical Practice of Inflammatory Bowel Disease-Associated Intestinal Neoplasia (English Version)

  2026cites this paper
• Practices and perceptions of 5-aminosalicylic acid use in Crohn’s disease: a nationwide survey of physicians in Korea by KASID Guidelines Taskforce Team

  2025cites this paper
• ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.

  2024cites this paper
• Education level and biologic therapy are the related factors of mucosal healing in Patients with Crohn's disease.

  2024cites this paper
• Usefulness of Serum Leucine-Rich Alpha-2 Glycoprotein as a Surrogate Marker of Small Bowel Mucosal Injury in Crohn’s Disease

  2023cites this paper
• The long-term effect on surgery-free survival of biological compared to conventional therapy in Crohn’s disease in real world-data: a retrospective study

  2023cites this paper
• Long‐term disease course, cost and prognosis of inflammatory bowel disease: epidemiological studies of a European and a Danish inception cohort

  2023cites this paper
• Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics

  2023cites this paper
• Crohn's Disease of the Elderly: Unique Biology and Therapeutic Efficacy and Safety.

  2022cites this paper
• Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia

  2022cites this paper
• Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis

  2022cites this paper
• 5-Aminosalicylic Acid Prevents Disease Behavior Progression and Intestinal Resection in Colonic and Ileocolonic Crohn's Disease Patients: A Retrospective Study

  2021cites this paper
• Continued 5ASA use after initiation of anti‐TNF or immunomodulator confers no benefit in IBD: a population‐based study

  2021cites this paper
• Clinical features of 44 patients with small bowel Crohn's disease.

  2021cites this paper
• Description of the inflammatory bowel disease natural history in Tehran province, Iran: Mixed panel approaches

  2021cites this paper
• Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.

  2021cites this paper
• AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease.

  2021cites this paper
• The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink

  2020cites this paper
• Management of the Elderly Inflammatory Bowel Disease Patient

  2020cites this paper
• Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.

  2019cites this paper
• Therapy for Crohn's Disease

  2019cites this paper
• Crohn's disease.

  2019cites this paper
• The IBD Control Questionnaire: the development and psychometric validation of a questionnaire for measuring inflammatory bowel disease control from the patient's perspective.

  2019cites this paper
• Evidence-based clinical practice guidelines for inflammatory bowel disease

  2018cites this paper
• Refocusing IBD Patient Management: Personalized, Proactive, and Patient‐Centered Care

  2018cites this paper
• [Second Korean Guidelines for the Management of Crohn's Disease].

  2017cites this paper
• The current therapeutic options for Crohn’s disease: from medical therapy to intestinal transplantation

  2017cites this paper
• Risk Stratification of Patients with Crohn's Disease: A Retrospective Analysis of Clinical Decision Making and Its Impact on Long-Term Outcome

  2017cites this paper
• An Update on Inflammatory Bowel Disease.

  2017cites this paper
• A probabilistic pathway score (PROPS) for classification with applications to inflammatory bowel disease

  2017cites this paper
• Second Korean guidelines for the management of Crohn's disease

  2017cites this paper
• Steroid dependency and trends in prescribing for inflammatory bowel disease – a 20‐year national population‐based study

  2016cites this paper
• Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?

  2016cites this paper
• Natural History of Crohn's Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based Study

  2016cites this paper
• Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease

  2016cites this paper
• Inflammatory Bowel Disease.

  2016cites this paper
• Asia–Pacific consensus statements on Crohn's disease. Part 2: Management

  2016cites this paper
• Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease.

  2016cites this paper
• Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal

  2015cites this paper
• Systematic review with network meta‐analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease

  2015cites this paper
• Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis.

  2015cites this paper
• The Role of Enteral Nutrition in Patients with Inflammatory Bowel Disease: Current Aspects

  2015cites this paper
• Management of Crohn’s disease – are guidelines transferred to clinical practice?

  2015cites this paper
• Combination therapy for the treatment of Crohn’s disease

  2015cites this paper
• Crohn’s disease: a clinical update

  2015influential citation
• The Impact of Timing and Duration of Thiopurine Treatment on First Intestinal Resection in Crohn's Disease: National UK Population-Based Study 1989–2010

  2014cites this paper
• Risks of Inflammatory Bowel Disease Treatment with Glucocorticosteroids and Aminosalicylates

  2013cites this paper
• International variation in medication prescription rates among elderly patients with inflammatory bowel disease.

  2013cites this paper
• Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.

  2013cites this paper
• Comparing medical treatments for Crohn's disease.

  2013cites this paper
• Ustekinumab for the treatment of Crohn's disease.

  2013cites this paper
• Reappraisal of total body irradiation followed by bone marrow transplantation as a therapy for inflammatory bowel disease.

  2013cites this paper
• KLASIČNI LIJEKOVI KOJI SE UPOTREBLJAVAJU U LIJEČENJU UPALNIH BOLESTI CRIJEVA

  2013cites this paper
• Top-Down or Step-Up Treatment in Crohn's Disease?

  2013cites this paper
• Tumor necrosis factor inhibitors for inflammatory bowel disease.

  2013cites this paper
• Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors.

  2013cites this paper
• Long-Term Clinical Outcomes and Factors Predictive of Relapse After 5-Aminosalicylate or Sulfasalazine Therapy in Patients With Intestinal Behcet Disease

  2012cites this paper
• Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease

  2012cites this paper
• Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.

  2012cites this paper
• Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan

  2012cites this paper
• Mild to Moderate Crohn's Disease

  2012cites this paper
• [Guidelines for the management of Crohn's disease].

  2012cites this paper
• An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease

  2011cites this paper
• Probiotics in Inflammatory Bowel Diseases and Associated Conditions

  2011cites this paper
• Guidelines for the management of inflammatory bowel disease in adults

  2011cites this paper
• Review article: remission rates achievable by current therapies for inflammatory bowel disease

  2011cites this paper
• Efficacy of 5-Aminosalicylates for the Maintenance of Remission in Crohn's Disease

  2011cites this paper
• Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease.

  2011cites this paper
• Medical management of Crohn's disease

  2011cites this paper
• Inflammatory bowel disease‐attributable costs and cost‐effective strategies in the United States: A review

  2011cites this paper
• Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease

  2011cites this paper
• Inflammatory bowel disease therapy: current state-of-the-art

  2011cites this paper
• Randomized, placebo‐controlled, double‐blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy

  2011cites this paper
• Crohn's disease.

  2011cites this paper
• Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis

  2011cites this paper
• Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.

  2011cites this paper
• Conventional medical management of inflammatory bowel disease.

  2011cites this paper
• Role of biological therapy for inflammatory bowel disease in developing countries

  2011influential citation
• Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco‐epidemiological approach

  2010cites this paper
• Inflammatory bowel disease in children: current trends

  2010cites this paper
• Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD.

  2010cites this paper
• Asian perspectives in the management of inflammatory bowel disease: Findings from a recent survey

  2010cites this paper
• Emerging drugs to treat Crohn's disease

  2010cites this paper
• Consensus guidelines for the management of inflammatory bowel disease.

  2010cites this paper
• 5-aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study.

  2010cites this paper
• Systematic Review of the Evidence Base for the Medical Treatment of Paediatric Inflammatory Bowel Disease

  2010cites this paper
• The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

  2010cites this paper
• Mild to Moderate Crohn’s Disease: Still Room for Step-Up Therapies?

  2009cites this paper
• Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD.

  2009cites this paper
• Place des 5-ASA dans le traitement des maladies inflammatoires cryptogénétiques de l’intestin

  2009cites this paper
• Crohn’s disease clinical issues and treatment: what the radiologist needs to know and what the gastroenterologist wants to know

  2009cites this paper
• Interventions for prevention of post-operative recurrence of Crohn's disease.

  2009cites this paper
• Budesonide for Crohn's disease

  2009cites this paper
• Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel - EPACT II.

  2009cites this paper
• Systematic review: does concurrent therapy with 5‐ASA and immunomodulators in inflammatory bowel disease improve outcomes?

  2009cites this paper
• Anti-tumour necrosis factor-alpha therapies in Crohn's disease.

  2009cites this paper
• Nutzen und Risiken der Immunsuppression bei chronisch entzündlichen Darmerkrankungen

  2008cites this paper
• Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.

  2008cites this paper
• Natural history of pediatric Crohn's disease: a population-based cohort study.

  2008cites this paper
• Traditional corticosteroids for induction of remission in Crohn's disease.

  2008cites this paper